Objective:The aim of this study was to investigate the effects of traditional Chinese medicine Anluohuaxianwan(ALHXW)on peroxisome proliferator-activated receptor-gamma(PPARγ)and nuclear factor-kappa B(NF-κB)signali...Objective:The aim of this study was to investigate the effects of traditional Chinese medicine Anluohuaxianwan(ALHXW)on peroxisome proliferator-activated receptor-gamma(PPARγ)and nuclear factor-kappa B(NF-κB)signaling pathways using a rat model of carbon model groups were gavaged with saline for 6 weeks.Liver function was measured,and liver fibrosis and necroinflammation were assessed.Protein and messenger RNA expression levels of PPARγ,NF-κB,and Inhibitorαof NF-κB(IκBα)were analyzed by Western blot and reverse transcription–quantitative polymerase chain reaction.Results:ALHXW markedly alleviated liver injury compared with the model group,as indicated by the improvements in disease status,the morphology of liver and spleen,the liver and spleen indexes,and liver function.The extent of liver fibrosis was improved,hepatic stellate cell activation was inhibited,the expression of PPARγand IκBαwas significantly higher,and the expression of NF-κB was significantly lower in the treatment group as compared with the model group.Conclusions:ALHXW treatment can alleviate CCl4-induced liver fibrosis in rats, and the potential antifibrogenic mechanisms may occur through the upregulation of PPARγ expression and downregulation of NF-κB/IκBα signaling pathway.展开更多
目的:系统评价安络化纤丸抗肝纤维化的疗效。方法:采用Jadad评分标准,通过分析软件Rev Man 5.0对多个研究结果的总体效应进行Meta分析。结果:17篇临床试验包含695例病例符合纳入标准,所有试验被评为低质量试验。安络化纤丸抗肝纤维化的...目的:系统评价安络化纤丸抗肝纤维化的疗效。方法:采用Jadad评分标准,通过分析软件Rev Man 5.0对多个研究结果的总体效应进行Meta分析。结果:17篇临床试验包含695例病例符合纳入标准,所有试验被评为低质量试验。安络化纤丸抗肝纤维化的疗效与对照组比较,差异均有统计学意义。结论:安络化纤丸治疗慢性肝炎肝纤维化具有较好的抗肝纤维化作用。展开更多
基金supported by a Cooperation Project between Peking University Health Science Center and Sunlon Pharmaceutical Co.,Ltd
文摘Objective:The aim of this study was to investigate the effects of traditional Chinese medicine Anluohuaxianwan(ALHXW)on peroxisome proliferator-activated receptor-gamma(PPARγ)and nuclear factor-kappa B(NF-κB)signaling pathways using a rat model of carbon model groups were gavaged with saline for 6 weeks.Liver function was measured,and liver fibrosis and necroinflammation were assessed.Protein and messenger RNA expression levels of PPARγ,NF-κB,and Inhibitorαof NF-κB(IκBα)were analyzed by Western blot and reverse transcription–quantitative polymerase chain reaction.Results:ALHXW markedly alleviated liver injury compared with the model group,as indicated by the improvements in disease status,the morphology of liver and spleen,the liver and spleen indexes,and liver function.The extent of liver fibrosis was improved,hepatic stellate cell activation was inhibited,the expression of PPARγand IκBαwas significantly higher,and the expression of NF-κB was significantly lower in the treatment group as compared with the model group.Conclusions:ALHXW treatment can alleviate CCl4-induced liver fibrosis in rats, and the potential antifibrogenic mechanisms may occur through the upregulation of PPARγ expression and downregulation of NF-κB/IκBα signaling pathway.
文摘目的:系统评价安络化纤丸抗肝纤维化的疗效。方法:采用Jadad评分标准,通过分析软件Rev Man 5.0对多个研究结果的总体效应进行Meta分析。结果:17篇临床试验包含695例病例符合纳入标准,所有试验被评为低质量试验。安络化纤丸抗肝纤维化的疗效与对照组比较,差异均有统计学意义。结论:安络化纤丸治疗慢性肝炎肝纤维化具有较好的抗肝纤维化作用。
